Volume 9, Number 8—August 2003
Multidrug-Resistant Shiga Toxin–Producing Escherichia coli O118:H16 in Latin America
To the Editor: We report the first isolation of a multiple antimicrobial drug–resistant strain of Shiga toxin–producing Escherichia coli (STEC) O118:H16 from cattle in Latin America. The strain was isolated during a study of fecal STEC in 205 healthy and 139 diarrheic cattle on 12 beef farms in the state of São Paulo, Brazil, in February 2000; one case of STEC was found in a 1-month-old calf with diarrhea. This bovine STEC O118:H16 strain showed resistance to eight antimicrobial substances; the following resistance (R)-genes were detected: ampicillin (blaTEM1-like), kanamycin and neomycin (aphA1), streptomycin (strA/B), sulphametoxazol (sul2), tetracyclin (tet[A]), trimethoprim (no dfrA1, A5, A7, A12, A14, or A17), and trimethoprim/sulphamethoxazol. The STEC O118:H16 strain from Brazil was found to be similar for virulence genes (Shiga toxin 1 [stx1], intimin beta 1 [eae β1], and EHEC-hemolysin [E-hlyA]) and for antimicrobial drug resistance to STEC O118:H16 strains, which were isolated in different countries of Europe (1). Beginning in 1986, STEC O118:H16 was identified as an emerging pathogen for calves and humans in Belgium and Germany (2–4). Cattle and human STEC O118:H16 isolates were similar in virulence attributes and antimicrobial drug resistance and belonged to a distinct genetic clone (1). Transmission of these pathogens from cattle to humans on farms was observed (5).
Beginning in 1996, STEC O118:H16 has become important as an emerging pathogen in humans and has been associated with bloody diarrhea and hemolytic uremic syndrome (2). Analysis of the antimicrobial resistance profiles showed that >96% of the European STEC O118:H16 strains showed resistance to one or more antimicrobial drugs in contrast to the 10% to 15% drug-resistant strains that were detected among STEC belonging to other serotypes (1,6,7). STEC O118:H16 showing multiresistance in up to eight different antimicrobial drugs predominated among younger isolates, indicating that drug resistance genes have accumulated over time in STEC O118:H16 strains. The frequency of antimicrobial drug resistance in STEC and Stx-negative E. coli in humans and animals was compared in a study by Schroeder et al. (8). Among human clinical E. coli isolates, antimicrobial resistance was less frequently observed in STEC than in Stx-negative strains, whereas in cattle, antibiotic-resistant strains were found at similar frequencies in both groups of E. coli. The relatively higher frequency of antimicrobial-resistant STEC in cattle was explained by the use of antimicrobial drugs in cattle production, whereas human infections with STEC are generally not treated with antibiotics (8). Cattle could thus be an important source of new emerging antibiotic-resistant STEC strains such as O118:H16.
The genetic basis of antimicrobial resistance in STEC O118:H16 is broad, including R-plasmids, integrons, transposons, and chromosomally inherited drug-resistance genes. Fluoroquinolone resistance has also been acquired by some STEC O118:H16 strains (1). The heterogenicity of antimicrobial drug–resistance patterns, the increase of multidrug-resistant strains over time of isolation, and the evidence for multiple aquisition and genetic location of R-determinants indicate that strains belonging to the STEC O118:H16 clone have a propensity to acquire and accumulate R-genes. The finding that multidrug-resistant STEC O118:H16 is isolated from cattle in South America indicates the global spread of this new emerging EHEC type.
- Maidhof H, Guerra B, Abbas S, Elsheikha HM, Whittam TS, Beutin L. A multiresistant clone of shiga toxin–producing Escherichia coli O118:[H16] is spread in cattle and humans over different European countries. Appl Environ Microbiol. 2002;68:5834–42.
- Beutin L, Zimmermann S, Gleier K. Human infections with Shiga toxin–producing Escherichia coli other than serogroup O157 in Germany. Emerg Infect Dis. 1998;4:635–9.
- Mainil J. Shiga/verocytotoxins and Shiga/verotoxigenic Escherichia coli in animals. Vet Res. 1999;30:235–57.
- Wieler LH, Vieler E, Erpenstein C, Schlapp T, Steinruck H, Bauerfeind R, Shiga toxin–producing Escherichia coli strains from bovines: association of adhesion with carriage of eae and other genes. J Clin Microbiol. 1996;34:2980–4.
- Beutin L, Bulte M, Weber A, Zimmermann S, Gleier K. Investigation of human infections with verocytotoxin-producing strains of Escherichia coli (VTEC) belonging to serogroup O118 with evidence for zoonotic transmission. Epidemiol Infect. 2000;125:47–54.
- Kobayashi H, Shimada J, Nakazawa M, Morozumi T, Pohjanvirta T, Pelkonen S, Prevalence and characteristics of Shiga toxin–producing Escherichia coli from healthy cattle in Japan. Appl Environ Microbiol. 2001;67:484–9.
- Schroeder CM, Zhao C, DebRoy C, Torcolini J, Zhao S, White DG, et al. Antimicrobial resistance of Escherichia coli O157 isolated from humans, cattle, swine, and food. Appl Environ Microbiol. 2002;68:576–81.
- Schroeder CM, Meng J, Zhao S, DebRoy C, Torcolini J, Zhao C, et al. Antimicrobial resistance of Escherichia coli O26, O103, O111, O128, and O145 from animals and humans. Emerg Infect Dis. 2002;8:1409–14.
Suggested citation for this article: Poikonen E, Lyytikäinen O, Anttila V-J, Ruutu P. Multidrug-resistant shiga toxin–producing Escherichia coli O118:H16 in Latin America. Emerg Infect Dis [serial online] 2003 Aug [date cited]. Available from: URL: http://wwwnc.cdc.gov/eid/article/9/8/03-0062
Please use the form below to submit correspondence to the authors or contact them at the following address:
Lothar Beutin, Division of Microbial Toxins, Department of Biological Safety, Robert Koch-Institute, Nordufer 20, D-13353 Berlin, Germany; fax: +49 30 4547 2673
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 22, 2010
- Page last updated: December 22, 2010
- Page last reviewed: December 22, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)